Crestor Study Will Boost Statin Demand

AstraZeneca's statin was found to cut cardiovascular risk in those with normal cholesterol by 45%. But are the potentially huge extra costs worth it?

In a study that will likely change medical practice, researchers reported that Crestor, a cholesterol-fighting statin made by AstraZeneca (AZN), reduced the risk of heart attack, stroke, and cardiovascular disease by a surprisingly robust 45% in people who do not have high cholesterol. The patients did have high levels of a protein associated with arterial inflammation that is not routinely measured.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.